SIRPA and lymphoma: In the first study of a subcutaneous Raji xenograft lymphoma model26 in immuno-compromised NOD/SCID mice, HX009 (10 mg/kg) induced significant growth delay (approximately 54% TGI, or Tumor growth inhibition = (1 − Vtreatment/Vcontrol) × 100), similar to SIRPα-Fc (53% TGI) (Fig. 3A), confirming the anti-lymphoma effects of a CD47 directed biologic in this immunocompromised xenograft model.